Treatment of Advanced AIDS Patients With Dextrin Sulfate
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00004987
Recruitment Status : Unknown
Verified June 2001 by NIH AIDS Clinical Trials Information Service. Recruitment status was: Active, not recruiting
The purpose of this study is to look at the safety and effectiveness of dextrin sulfate in AIDS patients who have failed conventional anti-HIV treatment.
Condition or disease
Drug: Dextrin 2-sulfate
Patients have intraperitoneal (IP) catheter placement done at study entry. Infusion with the carrier vehicle (icodextrin 4%) begins 2 weeks later, and 2 days after that, treatment with dextrin sulphate (DS) commences. DS is given three times per week. A nurse delivers initial treatments and the patient and caregiver will be trained to give subsequent treatments until DS has been given a total of 8 weeks. Patient evaluations are done regularly during treatment and observation continues for 24 weeks.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients may be eligible for this trial if they:
Have been diagnosed with AIDS and are under treatment to prevent opportunistic (AIDS-related) infection.
Have had a CD4 cell count greater than 50 microL for at least the past 3 months.
Have had a viral load of at least 50,000 copies/ml for at least the past 3 months.
Have used up all other treatment options.
Are able to understand and give written consent.
Patients may not be eligible for this trial if they:
Have been in any other study in the 6 weeks before beginning this study.
Have an active, opportunistic infection or other infection.
Have any other long-term medical condition or nervous disorder that might make it difficult for them to finish the study.